Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Nurix Therapeutics, Inc. (NASDAQ: NRIX)
NRIX Stock Predictions and Ratings
WSX Rating:
STRONG BUY
WSX Forecast (1yr):
41.10%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
100.80%
NRIX Stock Analysis
NRIX
PE Ratio:
NRIX
PEG Ratio:
Not Available
NRIX
Forward EPS Growth (12 month):
0.00%
NRIX
PS Ratio:
18.7
NRIX
PSG Ratio:
0.3
NRIX
Forward Revenue Growth (12 month):
55.10%
NRIX Articles
No data was found